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ABSTRACT Balamuthia mandrillaris is a pathogenic free-living amoeba that causes a
rare but almost always fatal infection of the central nervous system called granulo-
matous amoebic encephalitis (GAE). Two distinct forms of B. mandrillaris—a prolifer-
ative trophozoite form and a nonproliferative cyst form, which is highly resistant to
harsh physical and chemical conditions—have been isolated from environmental
samples worldwide and are both observed in infected tissue. Patients suffering from
GAE are typically treated with aggressive and prolonged multidrug regimens that of-
ten include the antimicrobial agents miltefosine and pentamidine isethionate. How-
ever, survival rates remain low, and studies evaluating the susceptibility of B. man-
drillaris to these compounds and other potential therapeutics are limited. To address
the need for more-effective treatments, we screened 2,177 clinically approved com-
pounds for in vitro activity against B. mandrillaris. The quinoline antibiotic nitroxoline
(8-hydroxy-5-nitroquinoline), which has safely been used in humans to treat urinary
tract infections, was identified as a lead compound. We show that nitroxoline inhib-
its both trophozoites and cysts at low micromolar concentrations, which are within a
pharmacologically relevant range. We compared the in vitro efficacy of nitroxoline to
that of drugs currently used in the standard of care for GAE and found that nitroxo-
line is the most potent and selective inhibitor of B. mandrillaris tested. Furthermore,
we demonstrate that nitroxoline prevents B. mandrillaris-mediated destruction of
host cells in cultured fibroblast and primary brain explant models also at pharmaco-
logically relevant concentrations. Taken together, our findings indicate that nitroxo-
line is a promising candidate for repurposing as a novel treatment of B. mandrillaris
infections.
IMPORTANCE Balamuthia mandrillaris is responsible for hundreds of reported cases
of amoebic encephalitis, the majority of which have been fatal. Despite being an ex-
ceptionally deadly pathogen, B. mandrillaris is understudied, leaving many open
questions regarding epidemiology, diagnosis, and treatment. Due to the lack of ef-
fective drugs to fight B. mandrillaris infections, mortality rates remain high even for
patients receiving intensive care. This report addresses the need for new treatment
options through a drug repurposing screen to identify novel B. mandrillaris inhibi-
tors. The most promising candidate identified was the quinoline antibiotic nitroxo-
line, which has a long history of safe use in humans. We show that nitroxoline kills
B. mandrillaris at pharmacologically relevant concentrations and exhibits greater po-
tency and selectivity than drugs commonly used in the current standard of care. The
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findings that we present demonstrate the potential of nitroxoline to be an impor-
tant new tool in the treatment of life-threatening B. mandrillaris infections.
KEYWORDS amoeba, antiparasitic agents, balamuthia, encephalitis, nitroxoline
The opportunistic protist pathogen Balamuthia mandrillaris causes rare but life-threatening infections of the central nervous system (CNS), termed balamuthia or
granulomatous amoebic encephalitis (GAE) (1, 2). Onset of the disease is gradual and
chronically develops over a few weeks to months in both immunocompromised and
immunocompetent individuals worldwide (1, 3). Presenting clinical symptoms include
but are not limited to fever, vomiting, neck stiffness, headache, nausea, personality
changes, and seizures (1, 3). These symptoms are nonspecific and overlap symptoms
caused by more common brain infections such as bacterial and viral meningitis as well
as noninfectious neuroinflammatory syndromes. Cutaneous presentation is less com-
mon and can produce symptoms ranging from painless swelling to ulceration and
formation of large lesions (4–6). Infections involving other organs ranging from the
lungs to the eye have also been documented (7, 8). Thus, B. mandrillaris-induced
encephalitis often goes unrecognized and diagnosis is frequently only made postmor-
tem. Several hundred cases have been reported; however, the actual disease burden is
likely underestimated (2, 9).
While systematic ecological studies of B. mandrillaris have not been performed,
free-living B. mandrillaris amoebae have been isolated from water, soil, and dust across
all continents (10–18). Cases of human and animal infections are also reported on all
continents but are most common in South America and the southern United States
(19–35) (reviewed in references 31, 32, and 33). B. mandrillaris is thought to be
transmitted by inhalation of contaminated aerosols or exposure via broken skin (36).
Fatal amoebic encephalitis has also occurred after solid-organ transplantation (37, 38).
Pathogenesis is believed to involve hematogenous spread to the CNS through pene-
tration of the blood-brain barrier, and amoebae are frequently observed around blood
vessels (3, 36).
Free-living amoebae such as Sappinia pedata, Acanthamoeba spp., and Naegleria
fowleri can also cause infection of the CNS with very poor prognosis (2, 39). Acantham-
oeba and Balamuthia are the most similar and are classified in the same eukaryote
supergroup (Amoebozoa: Acanthamoebidae) (40). The mode of infection employed by
Sappinia pedata and Acanthamoeba spp. is thought to be similar to that used by
Balamuthia, as encephalitis caused by these genera progresses over several weeks to
months and is associated with water or soil contact. Acute encephalitis caused by N.
fowleri is specifically associated with recreation in warm freshwater environments, with
presumed neuroinvasion of the amoeba by passing up the nose through the cribiform
plate to the brain (41). All of these pathogenic amoebae have a proliferative tropho-
zoite form and a dormant, thick-walled cyst form, while N. fowleri also has a motile
flagellate form. The cyst form of free-living amoebae is notoriously more resistant to
antimicrobials (42–47) and to a variety of abiotic stressors such as UV light (48–50). Such
attributes, along with the fact that drug sensitivities differ among genera, species, and
strains of free-living amoebae, have complicated studies in drug discovery (51).
Infection of the CNS by B. mandrillaris is almost always fatal, and no specific and
highly successful treatment regimen is known (45, 52). The CDC recommends the
following drugs for treatment of B. mandrillaris CNS infection: pentamidine isethionate,
miltefosine, fluconazole, flucytosine, sulfadiazine, azithromycin, and/or clarithromycin
(53). In vitro studies performed with the CDC-recommended drugs have shown little to
no inhibition of amoebic growth by fluconazole, sulfadiazine, and flucytosine, while
azithromycin, pentamidine isethionate, miltefosine, and voriconazole (a fluconazole
derivative) exhibit amoebicidal or amoebistatic activity (11, 42, 51). Current treatments
for B. mandrillaris CNS infections employing experimental combinations of these drugs
have produced inconsistent outcomes, including survival in some cases and fatality in
others (7, 19, 23, 27, 29, 30, 34, 54–62). As the efficacy and specificity of current
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treatments remain uncertain, there is a clear need to identify additional drugs that can
improve patient outcomes.
The goal of this study was to identify, from a set of clinically approved compounds,
candidates that have the potential to be repurposed for treatment of B. mandrillaris
infections. Here, we screened a library of 2,177 clinically approved compounds and
found that the quinoline antibiotic nitroxoline (8-hydroxy-5-nitroquinoline) exhibits
amoebicidal activity at low micromolar concentrations, well within the range of the
estimated plasma concentrations achieved with recommended oral dosing (63–65).
Through direct in vitro comparisons, we found that nitroxoline is a substantially more
potent and selective inhibitor of B. mandrillaris than three commonly used GAE
treatments currently recommended by the CDC. In addition to killing B. mandrillaris
trophozoites, nitroxoline treatment also causes encystment and substantially delays
recrudescence of active amoebae, which is significant considering the rapid decom-
pensation of patients suffering from GAE. Nitroxoline, with its ease of delivery and
favorable pharmacodynamic properties, has the potential to be used as an effective
treatment for GAE in singularity or in combination with drugs in the current standard
of care.
RESULTS
Identification of nitroxoline as an inhibitor of B. mandrillaris trophozoites in
vitro. Due to the extremely high mortality rate associated with Balamuthia mandrillaris
infections and the limited efficacy of current treatments, there is a clear need to identify
additional therapeutic strategies to improve patient outcomes in these rare but deadly
infections. Here, we established replicating axenic cultures of B. mandrillaris (ATCC
PRA-291) and screened 2,177 clinically approved compounds for reduction of tropho-
zoite viability following 72 h of treatment at 20 M. Compounds with high percent
inhibition (40% or above) and B-score (5 or above) were nominated for secondary
screening (Fig. 1A; see also Table S1A in the supplemental material). The remaining
compounds were annotated by class and delivery method to eliminate drugs approved
only for topical delivery or veterinary use, which have low therapeutic potential
(Table S1B). The selected candidate drugs were tested in dose-response assays with B.
mandrillaris trophozoites as well as HFF-1 and H4 human cell cultures to confirm their
activity and evaluate toxicity to human cells (Table S1C). Half-maximal inhibitory
concentration (IC50) values indicated that only two compounds, pentamidine isethio-
nate and nitroxoline, demonstrated adequate potency against B. mandrillaris without
high toxicity to human cells. Since the amoebistatic activity of pentamidine has
previously been described (46), we focused on further characterizing the novel activity
of nitroxoline as the lead compound identified by this screen.
Nitroxoline structure-activity relationship (SAR) experiments. Nitroxoline is cur-
rently in clinical use as an antimicrobial drug in certain European and Asian countries.
The hypothesized mechanism of action (MoA) is as a metal chelator that disrupts
biofilm formation (66). Nitroxoline and other 8-hydroxyquinolines have also previously
demonstrated in vitro anticancer activity, and free-radical metabolites are thought to be
involved in cell death (67). To test which of these mechanisms is applicable in killing B.
mandrillaris, we tested 19 commercially available analogs of nitroxoline for amoebicidal
activity. While nitroxoline itself remained the most potent compound tested, there was
a clear necessity for the 8-position hydroxyl group on the quinoline ring to retain high
activity (Fig. 2; see also Table S2). As demonstrated by the activity of
8-hydroxyquinoline (compound 2), the 5-position nitro group is not necessary for
activity, while in contrast, retaining the nitro group without the hydroxy group (com-
pound 3) significantly decreases activity. Replacing the nitro group at the 5 position of
the 8-hydroxyquinoline core with a variety of other functional groups, along with dual
5,7-position functionalization (compounds 4 to 13) results in several active but less
potent analogs with no clear trend due to aromatic electronic affects. The sulfonic acid
functionalized variant (compound 13) was the sole inactive compound among com-
pounds 4 to 13, which we speculate may have been due to differences in uptake or
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permeability. Lastly, phenanthroline (compound 14), a structurally similar bidentate
metal binding ligand, also demonstrated activity against B. mandrillaris. Taken together,
these results indicate a likely metal binding mechanism for the original nitroxoline
compound.
Direct comparison of nitroxoline to standard-of-care drugs for GAE treatment.
To evaluate nitroxoline as a potential drug to treat B. mandrillaris infections, we
compared the in vitro performance of nitroxoline to that of pentamidine isethionate,
miltefosine, and azithromycin, three drugs recommended by the CDC and commonly
used in treatment of GAE (53). We performed side-by-side dose-response experiments
to measure the efficacy of each drug against B. mandrillaris trophozoites and the
toxicity to different human cell types using the following cell lines: HFF-1 (fibroblast),
H4 (glial), U87 (glial), HEK-293T (kidney), and Hep-G2 (liver). Nitroxoline was the most
potent inhibitor of B. mandrillaris trophozoites, with an IC50 of 2.84 M compared to
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FIG 1 (A) Workflow for screening of clinically approved compounds for in vitro activity against B. mandrillaris. A primary screen of 2,177 clinically
approved compounds yielded 30 hits meeting the percent inhibition and B-score criteria, among which only 13 candidates were available for oral
or intravenous (IV) administration (see panel B). Secondary screening identified only one novel lead compound, nitroxoline, which displayed high
selectivity for inhibition of B. mandrillaris viability (Table S1C). Structure-activity relationship (SAR) experiments showed that 11 of 12 nitroxoline
analogs tested with potential metal binding domains remained active against B. mandrillaris, suggesting that metal binding plays a role in the
mechanism of inhibition by nitroxoline (Fig. 2). Comparison of nitroxoline to three drugs recommended by the CDC for treatment of B. mandrillaris
CNS infections (pentamidine isethionate, miltefosine, and azithromycin) indicates that nitroxoline is the most potent and specific inhibitor of B.
mandrillaris among the compounds tested (Fig. 3 and 4; see also Table S1). (B) Plot of percent inhibition relative to untreated controls and B-score
measured for each compound in a library of 2,177 clinically approved compounds. Raw data used to calculate these values are compiled in
Table S1A. Drugs recommended by the CDC for treatment of GAE are highlighted in blue. Drugs that are classified as antiseptic or topical and/or
have not been used in humans are shown in yellow. The quinoline antibiotic nitroxoline, which was the top hit identified in this screen, is
highlighted in red.
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IC50 values of 9.14 M, 63.23 M, and 244.10 M for pentamidine, miltefosine, and
azithromycin, respectively (Fig. 3A). Nitroxoline was also the only drug with an IC50
against B. mandrillaris that was lower than the half-maximal cytotoxic concentration
(CC50) for all cell lines tested. The average Log10 selectivity index (CC50 for human cell
toxicity/IC50 for B. mandrillaris inhibition) of nitroxoline across all cell lines was 0.832,
compared to 0.049, 0.102, and 0.409 for pentamidine, miltefosine, and azithromy-
cin, respectively (Fig. 3B [summarized in Table S3]). Combinations of nitroxoline with
miltefosine and with pentamidine isethionate showed generally additive inhibitory
effects on B. mandrillaris viability, suggesting that nitroxoline can be combined with
other amoebicidal drugs to produce greater inhibition (see Fig. S2 in the supplemental
material).
Encystment response of B. mandrillaris. In addition to a dose-dependent reduc-
tion in B. mandrillaris trophozoite viability, we also observed a general increase in the
ratio of cysts to trophozoites correlated with increasing concentrations of some drugs.
We investigated the propensity of nitroxoline, pentamidine isethionate, miltefosine,
and azithromycin to induce encystment of B. mandrillaris by counting the number of
cysts and trophozoites in culture samples following 72 h of treatment with different
drug concentrations. We observed a dose-dependent reduction in the number of
trophozoites in the population for all four drugs. Nitroxoline and pentamidine isethio-
nate caused an increase in both the total number and the proportion of cysts in the
population, while no substantial number of cysts was observed at any concentration of
miltefosine or azithromycin (Fig. 4A to D). Because encystment appears to occur as a
response to certain drug treatments, we also assessed the ability of each drug to inhibit
the viability of preformed B. mandrillaris cysts. We induced encystment by sustained
exposure to 12% galactose and conducted dose-response viability measurements for
each drug. Nitroxoline was again the most potent inhibitor of cysts, with an IC50 of
15.48 M compared to IC50 values of 26.26 M, 76.48 M, and 788.4 M for pentami-
dine, miltefosine, and azithromycin, respectively (Fig. 4E). While nitroxoline, pentami-
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FIG 2 Structure-activity relationship experiments suggest that nitroxoline inhibits B. mandrillaris through
a mechanism related to metal binding. Structures and IC50 values are shown for nitroxoline and select
analogs; additional compounds are shown in Table S2. Nitroxoline is made up of a quinoline core with
a nitro group at the 5 position and a hydroxyl group at the 8 position. Analogs lacking the 8-position
hydroxyl group were generally inactive, with IC50 values greater than 80 M (e.g., 5-nitroquinoline
[compound 3]). Twelve nitroxoline analogs with predicted metal binding activity were tested, and of
these, 1,10-phenanthroline (compound 14) and 10 of 11 compounds with an 8-position hydroxyl group
(e.g., 8-hydroxyquinoline [compound 2]) were active, with IC50 values ranging from 17 to 60 M. The only
inactive analog with an 8-position hydroxyl group was 8-hydroxy-5-quinolinesulfonic acid (compound
13). Variance of the 5-position nitro group reduced potency compared to nitroxoline, but no trend
related to aromatic electronic effects is apparent.
Inhibition of Balamuthia mandrillaris by Nitroxoline ®
September/October 2018 Volume 9 Issue 5 e02051-18 mbio.asm.org 5
dine, and azithromycin were considerably less potent inhibitors of cyst viability than of
trophozoite viability, miltefosine inhibited the two forms of B. mandrillaris at similar
concentrations (Table S3).
Delayed recrudescence of B. mandrillaris treated with nitroxoline. Nitroxoline
and the tested standard-of-care drugs induce various combinations of distinct and
intermediate B. mandrillaris phenotypes, including death and encystment. Though it is
assumed that drug-induced phenotypes such as encystment affect the rate of amoeba
population growth and host cell destruction, the magnitude and duration of these
effects are unknown. To assess how rapidly amoeba populations recover and proliferate
following drug treatment, we developed a recrudescence assay wherein we treated B.
mandrillaris trophozoite cultures with various concentrations of nitroxoline, pentami-
dine, or miltefosine for 72 h, removed drug, and then added the remaining amoebae
to a monolayer of HFF-1 cells in the absence of drug. The posttreatment recovery time
was measured as the number of days required for each B. mandrillaris population to
clear 100% of the host cells. Treatments that completely eliminated B. mandrillaris
populations were determined by observing no live trophozoites or destruction of host
cells at any point during the 28-day experiment. We found that 7 M and 14 M
pentamidine delayed recovery of B. mandrillaris by 1 to 2 weeks but that increasing the
dose from 14 M to 56 M delayed recovery by only an additional 3 days (Table S1).
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FIG 3 Potency and selectivity for inhibition of B. mandrillaris viability by nitroxoline, pentamidine
isethionate, miltefosine, and azithromycin. (A) Dose-response curves show the effect of nitroxoline (red),
pentamidine isethionate (black), miltefosine (blue), and azithromycin (gray) on the viability of B. man-
drillaris trophozoite populations following 72 h of treatment. Data points represent means and standard
errors of results from at least three independent biological replicates. Nitroxoline was the most potent
inhibitor of B. mandrillaris viability, with an IC50 of 2.84 M. (B) Heat map showing the Log10 selectivity
index (human cell CC50/B. mandrillaris IC50) for nitroxoline, pentamidine, isethionate, miltefosine, and
azithromycin calculated from the ratio of human cell CC50 to B. mandrillaris IC50. Nitroxoline exhibited the
greatest mean Log10 selectivity index at 0.832 and was the only drug with a positive Log10 selectivity
index (comparing B. mandrillaris inhibition to the results from all cell lines tested).
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Consistent with the steep Hill slope observed in dose-response experiments, miltefos-
ine caused very little delay in clearance time at 56 M but completely eliminated B.
mandrillaris populations at 112 M. In contrast, nitroxoline delayed amoeba recovery
by 2 to 3 weeks at low micromolar concentrations and completely eliminated B.
mandrillaris populations at 28 M.
Protective effect of nitroxoline in a primary human brain tissue model. Findings
from the recrudescence assays suggest that nitroxoline treatment may significantly
impede destruction of host cells in the context of B. mandrillaris infection. To further
explore this possibility, we performed experiments modeling B. mandrillaris infection
and nitroxoline treatment in primary human brain tissue. Human cortical tissue slices
were exposed to B. mandrillaris trophozoites and simultaneously treated with nitroxo-
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FIG 4 Relationship of drug treatment to B. mandrillaris encystment. (A to D) Changes in the number of
trophozoites (blue) and cysts (red) in B. mandrillaris populations following 72 h of treatment with various
concentrations of nitroxoline (A), pentamidine isethionate (B), miltefosine (C), and azithromycin (D). Low
micromolar concentrations of nitroxoline and pentamidine isethionate caused an increase in the total
number of cysts observed in B. mandrillaris populations and an increase in the ratio of cysts to
trophozoites. No increase in encystment was observed in B. mandrillaris populations treated with
miltefosine or azithromycin. (E) Dose-response curve showing the effect of nitroxoline (red), pentamidine
isethionate (black), miltefosine (blue), and azithromycin (gray) on the viability of preformed B. mandril-
laris cysts. Nitroxoline was the most potent inhibitor of cysts, with an IC50 of 15.48 M. Cysts were
substantially less sensitive than trophozoites (Fig. 2A) to all drugs except for miltefosine, which had
similar IC50 values for inhibition of both B. mandrillaris forms.
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line or vehicle (dimethyl sulfoxide [DMSO]) for 20 h before media were changed to
remove drug or vehicle. Tissues were cultured for 4 days and then evaluated for
damage by microscopic examination (Fig. 5; see also Fig. S3). Untreated tissues showed
widespread damage following B. mandrillaris exposure, including loss of distinct tissue
edges and reduction of cell density (Fig. 5B). Large numbers of highly motile B.
mandrillaris trophozoites were present at the edges of tissues and were intermixed with
human cells (see Movies S1 to S3 in the supplemental material). In contrast, nitroxoline-
treated tissues did not show signs of B. mandrillaris-mediated destruction and appeared
to be similar to uninfected tissues (Fig. 5A and C). Cysts with little to no motility were
observed outside the boundaries of tissues (Movie S4). While these findings are
qualitative, the large-scale differences in tissue morphology observed in this experi-
ment are consistent with the possibility that nitroxoline has a protective effect on host
tissue in the context of B. mandrillaris infection.
DISCUSSION
GAE caused by Balamuthia mandrillaris is almost always fatal (19–34). Because there
is no established treatment for GAE, patients commonly receive experimental combi-
nations of antimicrobial agents in aggressive and prolonged treatment regimens with
mixed outcomes (7, 19, 23, 27, 29, 30, 34, 54–62). In the present study, we aimed to
address the critical need for new treatments of GAE by identifying novel amoebicidal
compounds. Because our goal was to identify candidate drugs with established safety
and pharmacodynamic profiles, we chose to screen a library of 2,177 clinically approved
compounds. Based on the criteria of B-score and percent inhibition of B. mandrillaris
viability, we selected 12 compounds from the primary screen for follow-up screening
(Fig. 1A; see also Table S1B in the supplemental material). Secondary screening elimi-
nated all candidate compounds on the basis of low potency for inhibition of B.
mandrillaris or high toxicity to human cells, with the exception of the quinoline
antibiotic nitroxoline. Nitroxoline demonstrated promising potency and selectivity for
FIG 5 Nitroxoline prevents B. mandrillaris-mediated destruction of human brain tissue explants. Each
panel shows an image representative of two tissues 96 h after exposure to the indicated conditions.
Media were changed at 20 h postinfection to remove nitroxoline or vehicle. (A) Uninfected, untreated
(vehicle only) tissues had distinct edges and maintained cell density throughout culture. (B) B.
mandrillaris-infected, untreated (vehicle only) tissues show widespread damage, particularly at edges,
where loss of cell density and disorder of tissue structure are apparent. Large numbers of B. mandrillaris
trophozoites are observed intermixed with human cells and outside the tissue (lower half of image). (C)
B. mandrillaris-infected tissues treated with 35 M nitroxoline simultaneously with inoculation do not
show signs of tissue damage or loss of cell density and maintain distinct edges similar to those of
uninfected tissues. Clusters of B. mandrillaris cysts are observed outside the boundaries of the tissue.
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B. mandrillaris inhibition, which led us to focus our efforts on further investigating its
novel amoebicidal activity.
We performed side-by-side experiments to directly compare the in vitro efficacy of
nitroxoline with respect to B. mandrillaris inhibition to the efficacy of pentamidine
isethionate, miltefosine, and azithromycin, three drugs recommended by the CDC for
treatment of GAE and commonly used in case reports (29, 30, 53–55, 57). We found that
nitroxoline was the most potent inhibitor of B. mandrillaris trophozoite viability, with an
IC50 of 2.84 M and IC99 of 7.54 M (Fig. 3A). To estimate the selectivity of each drug,
we also measured the toxicity of each compound to five different human cell lines. For
pentamidine, miltefosine, and azithromycin, drug concentrations that reduced B. man-
drillaris viability also caused significant toxicity to human cells, giving very small
selectivity indices (Fig. 3B). In contrast, nitroxoline had an IC50 for B. mandrillaris
inhibition that was lower than the CC50 for all cell lines tested and had the highest
mean selectivity index value (Fig. 3B; see also Table S3).
B. mandrillaris and other free-living amoebae have a dormant, thick-walled cyst form
which is highly resistant to several types of environmental stress, including exposure to
some compounds that are toxic to the trophozoite form (44, 46, 48, 50). A previous
study postulated that the transition from the trophozoite form to the cyst form can be
triggered under a variety of conditions, including chemical stress (68), raising the
possibility that treatment with amoebicidal or amoebistatic drugs may induce encyst-
ment. To investigate this possibility, we quantified the frequency of cysts observed in
B. mandrillaris populations treated with different drug concentrations. We observed
that low micromolar concentrations of nitroxoline and pentamidine isethionate caused
increases in the total number and proportion of cysts in B. mandrillaris populations
(Fig. 4A and B). In contrast, miltefosine and azithromycin were not observed to induce
encystment at any concentration (Fig. 4C and D). These data support the possibility that
B. mandrillaris encystment occurs as a response to some but not all compounds that are
toxic to trophozoites. We suggest that compounds which promote encystment in
addition to killing trophozoites may provide additional benefit in the context of
infection by slowing or halting the rapid tissue destruction by trophozoites.
Because it is common for both cysts and trophozoites to be found in B. mandrillaris-
infected tissue, it is important to understand the efficacy of amoebicidal drugs against
both stages (69). To address this issue, we performed side-by-side dose-response
experiments with homogenous populations of cysts or trophozoites treated with
nitroxoline, pentamidine isethionate, miltefosine, and azithromycin. We found that
cysts were less sensitive than the trophozoites to all four drugs (Table S3). The
difference in sensitivity was marginal for miltefosine and greatest for nitroxoline, which
had an IC50 for cyst inhibition 6-fold higher than the IC50 for trophozoite inhibition.
Nevertheless, nitroxoline remained the most potent inhibitor of preformed B. mandril-
laris cysts, with an IC50 of 15.48 M.
Viability measurements of drug-treated B. mandrillaris cultures reflect a complex
population phenotype that includes various degrees of both death and encystment.
These measurements are not sufficient to predict the rate at which populations
recrudesce following treatment, which is an important factor in evaluating the overall
efficacy of different treatments. We chose to address this aspect of treatment efficacy
by performing recovery assays in which B. mandrillaris populations were exposed to
various drug treatments, removed from drug, and then cocultured with monolayers of
human cells until the host cells were fully consumed. As predicted, increasing drug
concentrations caused greater delays to B. mandrillaris recrudescence and host cell
destruction (Table 1). Surprisingly, even low micromolar concentrations of nitroxoline
near the IC50 for trophozoite inhibition delayed B. mandrillaris-mediated host cell
destruction by 2 to 3 weeks. This assay also served as a sensitive method to detect very
low numbers of surviving amoebae due to the large population expansion occurring
over the 28-day experiment duration. Importantly, this sensitive assay allowed us to
infer that B. mandrillaris populations had been completely eliminated by drug treat-
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ment when we observed no signs of amoeba population recovery after 28 days of
coculture with host cells.
Using this method, we determined that concentrations of 28 M nitroxoline and
112 M miltefosine completely eliminated B. mandrillaris populations. These data are
consistent with viability inhibition experiments in indicating that nitroxoline is the most
potent inhibitor of B. mandrillaris tested. The promising results of this experiment
suggest that nitroxoline may be able to fully eliminate B. mandrillaris infection if
sufficiently high concentrations are reached and is likely to cause substantial delays
with respect to host tissue damage even at lower concentrations. This is supported by
our findings indicating that nitroxoline prevented B. mandrillaris activity and tissue
destruction in a primary human brain tissue model (Fig. 5; see also Movie S1 to S4 in
the supplemental material). Together, these findings suggest that nitroxoline substan-
tially impedes host tissue destruction by B. mandrillaris in vitro. Given the rapid
progression of pathogenesis that is characteristic of GAE, any impediment to tissue
destruction could significantly improve patient prognosis.
The known safety and pharmacokinetic properties of nitroxoline suggest further
promise for its therapeutic value as an inhibitor of B. mandrillaris. Nitroxoline has been
safely used for over 50 years in the treatment of urinary tract infections, with minimal
adverse effects reported (70). Nitroxoline is available in oral and intravenous adminis-
tration forms and is typically dosed at 600 to 800 mg/day for adults, resulting in
maximal plasma concentrations (Cmax) of up to approximately 30 M (5.6 mg/liter)
(63–65), which is 10-fold higher than the IC50 for B. mandrillaris trophozoites in vitro
(Fig. 3A; see also Table S3). Although the extent to which nitroxoline crosses the blood
brain barrier is unknown, a recent study showed that systemically delivered nitroxoline
exhibits efficacy against gliomas in mice, implying that efficacious concentrations
reached the brain in that model (71). In addition, we previously noted that B. mandril-
laris frequently causes necrotizing vasculitis in the CNS with extensive blood-brain
barrier (BBB) breakdown, which may affect the bioavailability of systemically adminis-
tered drugs in the CNS of patients actively suffering from GAE (3, 36, 57). Furthermore,
given the extreme severity of GAE, intrathecal drug delivery can be performed to
maximize drug concentrations reaching the brain (2, 72). While many variables may
affect the in vivo efficacy of nitroxoline as well as the concentrations that can be
TABLE 1 Recrudescence time of active B. mandrillaris following drug treatment
Treatment
Mean no. of days for host
cell clearance  SE
Vehicle only
0.28% (vol/vol) DMSO 1.33 0.33
1.12% (vol/vol) water 1.67 0.67
Nitroxoline (in DMSO)
3.5 M 15.33 0.67
7 M 19 0.58
14 M 22 2.08
28 M NRTa
Pentamidine isethionate (in water)
3.5 M 1.33 0.33
7 M 7 1.15
14 M 13 2.51
28 M 15.33 2.56
56 M 16 2
Miltefosine
28 M 1.5 0.33
56 M 3.5 2.64
84 M 28b
112 M NRTa
aNRT, no recovery of trophozoites or host cell destruction observed through 28 days.
bIncomplete recovery of trophozoites and destruction of host cells on day 28.
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achieved in relevant compartments, the literature suggests that the in vitro efficacious
concentrations that we demonstrated are well within a pharmacologically relevant
range.
The in vitro results presented in this study strongly indicate that nitroxoline warrants
further investigation as a potential treatment for B. mandrillaris infections. As there
were many variables that were untested in our study that may affect the efficacy of
nitroxoline in vivo, future work will ideally focus on providing in vivo validation of the
amoebicidal activity of nitroxoline. In particular, in vivo studies will determine if
efficacious concentrations of nitroxoline reach the relevant tissues as well as provide
comparative evidence for amoebicidal activity with respect to currently recommended
compounds. We note that nitroxoline is an approved compound in several countries,
with an established safety profile (70), and it is possible that it could be considered as
an emergency experimental treatment in dire cases of GAE. In particular, since the
current standard of care generally consists of experimental combinations of several
antimicrobial agents, adding nitroxoline to these regimens may be a reasonable step in
the effort to improve patient prognosis. Although our SAR experiments did not identify
any analog that matched the potency of nitroxoline, medicinal chemistry optimization
may still be beneficial for a better understanding of possible mechanisms of action and
efforts to improve drug specificity. The similarity of B. mandrillaris to other free-living
amoebae such as Acanthamoeba spp. and Naegleria fowleri raises the intriguing pos-
sibility that nitroxoline or related compounds may also have activity against these
pathogens.
MATERIALS AND METHODS
Human cell lines. Hep-G2 (ATCC HB-8065), U87 (gift of Jonathan Weissman, University of California,
San Francisco [UCSF]), H4 (ATCC HTB-148), and HEK-293T (ATCC CRL-3216) cells were cultured in
Dulbecco’s modified Eagle’s medium (Gibco) containing 10% (vol/vol) fetal bovine serum (FBS) (Gibco),
2 mM L-glutamine, 100 U/ml penicillin/streptomycin (Gibco), and 10 mM HEPES buffer. HFF-1 cells (ATCC
SCRC-1041) were cultured in DMEM containing 15% (vol/vol) FBS, 2 mM L-glutamine, 100 U/ml penicillin/
streptomycin, and 10 mM HEPES buffer (Gibco). All mammalian-cell incubation steps were carried out at
37°C with 5% CO2. All cell lines were tested for mycoplasma contamination using a Lonza Mycoalert
mycoplasma detection kit (Lonza).
Balamuthia mandrillaris propagation, handling, and encystment. Balamuthia mandrillaris (ATCC
PRA-291) was maintained axenically in 150-cm2 flasks (Corning) containing modified Cerva’s medium
(axenic medium) with the following formulation: 20 g of Bacto Casitone (Difco), 68 ml of 10 Hanks’
balanced salt solution (Gibco), 10% fetal bovine serum, and 1 penicillin-streptomycin (200 IU/ml to
200 g/ml) (73). Axenic growth of B. mandrillaris resulted in 2 105 to 3 105 amoebae/ml in log phase.
Routine subculturing was performed every 3 to 4 days by transferring 5 ml of amoebae into 15 ml of fresh
axenic media.
Following the findings of a previous study, encystment of B. mandrillaris was induced by galactose
exposure (74). B. mandrillaris trophozoites were grown to log phase in axenic media, and galactose was
added to reach a final concentration of 12% (vol/vol). Amoebae were cultured in the induction medium
until trophozoites were no longer observed (approximately 10 days). Galactose-induced cysts transition
back to trophozoites after approximately 3 days of incubation in galactose-free axenic medium. There-
fore, all assays with cysts were completed in the induction medium. To quantify amoebae for use in
experiments, actively growing trophozoites or recently induced cysts were centrifuged at 3,000 rpm for
5 min, resuspended in axenic medium, and counted with a disposable hemocytometer (SKC, Inc.). All
incubation steps for B. mandrillaris growth were carried out at 37°C with 5% CO2.
Primary drug screening of Balamuthia mandrillaris trophozoites in vitro. Screening of a clinically
approved library of compounds, compiled by the Small Molecule Discovery Center (SMDC) at the UCSF,
was completed at 20 M in 0.2% DMSO. All 2,177 drugs in the library were stored as 10 mM stocks
dissolved in 100% DMSO (Sigma-Aldrich) at 20°C. B. mandrillaris amoebae were resuspended in axenic
medium and distributed into opaque 384-well plates (Corning) at a density of 3,000 amoebae per well
using a BioMek NX liquid handler. Negative-control wells were treated with vehicle only (0.2% DMSO in
axenic medium), and positive-control wells simulating total destruction of amoebae were seeded with
amoeba lysate generated by 3 consecutive freeze-thaw cycles. Following 72 h of incubation, 30 l of
CellTiter Glo reagent (CTG; Promega) was added to each well. The luminescence was measured with a
Promega GloMax-Multi plate reader at 2, 4, and 8 h after CTG addition. The percent inhibition of B.
mandrillaris was calculated based on the CTG luminescence measurements of treated wells relative to
both positive and negative controls using the following equation: percent inhibition  100  100*[(test
well intensity  positive-control intensity)/(negative-control intensity  positive-control intensity)]. The
B-score, representing a plate-based statistical approach for correcting row, column, and edge effects, was
also calculated for each compound in the library (75). Raw luminescence measurements and computed
inhibition values are displayed in Table S1A in the supplemental material. Hits represented compounds
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with a B-score of approximately 5 or above and percent inhibition of approximately 40% or above
(Table S1B). Hit compounds that are approved only for topical administration or veterinary use were not
tested in secondary screening (highlighted in yellow in Table S1B and Fig. 1B). Compounds identified in
the primary screen that did not exhibit activity upon repurchase of fresh compound were removed from
consideration in the screening funnel.
Secondary drug screening against B. mandrillaris trophozoites and HFF-1 and H4 human cells
in vitro. Secondary screening of hit compounds consisted of dose-response experiments to measure the
toxicity of each compound to B. mandrillaris trophozoites, HFF-1 human fibroblast cells, and H4 human
neuroglioma cells. Four 384-well plates were prepared prior to addition of drug as follows: one opaque
plate (Corning) seeded with 3,000 HFF-1 cells per well in 60 l complete media, one opaque plate seeded
with 2,000 H4 cells per well in 60 l complete media, one opaque plate containing 30 l axenic media,
and one clear plate (Corning) containing 30 l axenic media. Opaque plates were used to measure the
viability of trophozoites in the CTG assay, and clear plates were used for microscopic examination of cyst
formation. HFF-1 and H4 plates were seeded 24 h prior to drug addition. The selected primary screen hits
were added from 10mM DMSO stocks into wells of all four test plates to reach final concentrations
ranging from 0.06 M to 30 M (10 concentrations, 2-fold serial dilution). Negative-control wells received
concentrations of DMSO corresponding to the amount of DMSO in each tested drug well (reaching a
maximum of 0.3% DMSO). B. mandrillaris trophozoites were resuspended in axenic media and added to
the plates containing drug dilutions in axenic media at a density of 3,000 amoebae per well in a final
volume of 60 l media. All plates were incubated for 72 h. Throughout the incubation period, the
clear-bottom B. mandrillaris plate was monitored for large-scale changes to population encystment in
response to drug treatment. After the 72-h incubation, 30 l of CTG reagent was added to all wells of
the opaque assay plates and luminescence was measured with a Promega GloMax-Multi plate reader
at 2, 4, and 8 h after CTG addition. IC50 values for inhibition of B. mandrillaris viability were determined
using the GraphPad Prism 4-parametric sigmoidal curve-fitting model, with the bottom and top
constraints set to 0 and 1, respectively (Table S1C).
Nitroxoline structure-activity relationship experiments. Nineteen commercially available analogs
of nitroxoline were selected for structure-activity relationship (SAR) experiments based on variances in
functional groups that may play a role in the observed mechanism of action (compound sourcing and
data are presented in Table S2). B. mandrillaris was grown to log phase axenically and plated at 4,000
amoebae per well in opaque 96-well plates. Each nitroxoline analog was dissolved in 100% DMSO at
10 mM. Analog stocks were serially diluted in water to generate 8-point dilution series, which were then
used to treat assay wells containing B. mandrillaris trophozoites at final concentrations ranging from
0.14 M to 300 M (8 concentrations, 3-fold serial dilution) in a final volume of 100 l. After incubation
for 72 h, 50 l of CTG was added to all assay wells. Luminescence was measured using a Promega GloMax
Multi luminometer 2, 4, and 8 h after CTG addition. IC50 values were determined using the GraphPad
Prism 4-parametric sigmoidal curve-fitting model with bottom and top constrains of 0 and 1, respec-
tively.
Dose-response experiments with HFF-1, H4, U87, Hep-G2, and HEK 293T cells and Balamuthia
mandrillaris trophozoites and cysts. B. mandrillaris trophozoites were seeded at 4,000 amoebae per
well into opaque and clear-bottom 96-well plates (Corning). Homogenous populations of B. mandrillaris
cysts generated by galactose induction were seeded at 4,000 amoebae per well into opaque 96-well
plates. HFF-1 (fibroblast), H4 (glial), U87 (glial), HEK-293T (kidney), and Hep-G2 (liver) cells were seeded
at 3,000 cells per well in opaque 96-well plates 24 h prior to addition of drug. Stocks of nitroxoline
(Selleck Chemicals) were dissolved in 100% DMSO at 10 mM. Stocks of azithromycin (Selleck Chemicals),
pentamidine isethionate (Selleck Chemicals), and miltefosine (Selleck Chemicals) were dissolved in water
at 10 mM. Drug stocks were serially diluted in water to generate 12-point dilution series, which were then
used to treat assay wells containing B. mandrillaris or human cells at final concentrations ranging from
0.39 M to 400 M in 100-l total well volumes. Control wells were treated with vehicle (DMSO or water)
at concentrations corresponding to the final vehicle concentrations in each drug dilution series. After
incubation for 72 h, 50 l of CTG was added to all assay wells. Luminescence was measured with a
Promega GloMax-Multi plate reader 2, 4, and 8 h after CTG addition. All dose-response experiments
were performed with at least three independent biological replicates. IC50 values were determined as
previously described. To quantify encystment under treated and untreated conditions, amoebae in
individual assay wells were resuspended thoroughly and the number of cysts and number of tropho-
zoites in 10-l samples were counted by the use of a hemocytometer (SKC, Inc.). Cysts and trophozoites
are morphologically distinct, making them simple to distinguish with bright-field microscopy (example
images are shown in Fig. S1 in the supplemental material). Encystment assays were performed with three
independent biological replicates.
Experiments measuring the effect of drug combinations were carried out similarly to the dose-
response experiments described above. B. mandrillaris trophozoites were seeded into opaque 96-well
plates (Corning) at a density of 4,000 amoebae per well and then treated with concentrations of
nitroxoline that differed across the rows of each plate and with concentrations of either miltefosine or
pentamidine isethionate that differed down the columns to generate 7-by-7 dose combination matrices.
Final drug concentrations ranged from 0.5 to 10 M, from 10 to 100 M, and from 1 to 100 M for
nitroxoline, miltefosine, and pentamidine isethionate, respectively. After incubation with drug or vehicle
was performed for 72 h, CTG was added to all assay wells and luminescence was measured with a
Promega Glomax-Multi plate reader. The percent effect of each drug combination was calculated as the
reduction in luminescence value relative to vehicle-only controls. The additive effect of drug combina-
tions was assessed using the excess over highest single agent (EOHSA) model (76, 77). EOHSA values
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were calculated using the equation EOHSA Ecombo EHSA, where Ecombo is the percent effect of a given
dose combination and EHSA is the percent effect of the most active (highest) single agent in the drug pair.
Drug combination experiments were performed with three independent replicates.
Balamuthia mandrillaris recrudescence assays. Populations of B. mandrillaris were diluted to
2.5 105 amoebae in 10 ml media and were treated with 3.5, 7, 14, 28, 56, 84, and 112 M nitroxoline,
pentamidine isethionate, or miltefosine and incubated for 72 h. Following incubation, all remaining
amoebae in each population (various mixtures of cysts and trophozoites) were pelleted at 3,000 rpm for
5 min and resuspended in drug-free HFF-1 medium. Each resuspended B. mandrillaris population was
placed on a monolayer of HFF-1 cells that were seeded at 106 cells per flask in 10 ml at 24 h prior to
inoculation. At that cell density, untreated amoebae typically consume 100% of HFF-1 monolayers within
24 h. Coculture flasks containing amoebae and HFF-1 cells were incubated until 100% of the HFF-1
monolayer was consumed as observed by daily microscopic inspection or until the predetermined
endpoint of the experiment at 28 days post-B. mandrillaris inoculation was reached. The day on which
complete clearance of the HFF-1 monolayer occurred was recorded for all conditions. All recrudescence
assays were performed with three independent biological replicates. These methods were adapted from
a minimum trophozoite amoebicidal concentration (MTAC) assay that was conducted with monolayers
of MA104 monkey kidney cells (42).
Primary brain tissue model. Deidentified tissue samples were collected with previous patient
consent in strict observance of the legal and institutional ethical regulations. Protocols were approved
by the Human Gamete, Embryo, and Stem Cell Research Committee (institutional review board) at the
University of California, San Francisco. Primary brain tissue samples were sectioned perpendicularly to
the ventricle to obtain slices 300 m thick and2.5 mm2 in surface area, using a Leica VT1200S vibrating
blade microtome and artificial cerebrospinal fluid containing 125 mM NaCl, 2.5 mM KCl, 1 mM MgCl2,
1 mM CaCl2, and 1.25 mM NaH2PO4. Explants were transferred to slice culture insertions (Millicell) in
6-well culture plates and were cultured with media containing 66% Eagle’s basal medium, 25% Hanks
balanced salt solution, 5% fetal bovine serum, 1% N-2 supplement, 1 penicillin-streptomycin, and
glutamine in a 37°C incubator with 5% CO2. At 12 h after plating, slices were inoculated with 104 B.
mandrillaris trophozoites in 20 l of complete media containing vehicle (DMSO) or 35 M nitroxoline,
which was added dropwise to the slice surface. Media below the cell culture insert was adjusted to
matching vehicle or nitroxoline concentrations. At 20 h postinoculation, media below the cell culture
insertion were replaced with fresh media containing no drug. At that time, amoebae on top of the
insertion surrounding and within the tissue were left undisturbed. Bright-field and phase contrast images
were captured during the live culture experiment at magnifications of 4, 10, and 20 using an Evos
FL Cell Imaging System. At 4 days postinoculation, slices were gently fixed in 3.7% paraformaldehyde
(PFA) for 4 h at 4°C and then rinsed with phosphate-buffered saline (PBS), stained for 2 h at room
temperature with DAPI (4=,6-diamidino-2-phenylindole) (0.3 M)–PBS–1% Triton X-100, and then
mounted with ProLong Gold antifade mountant (Thermo). Images of stained tissue were obtained with
a Nikon Ti spinning disk confocal microscope at20 magnification. Confocal z-stacks were projected and
adjusted in ImageJ (78). Bright-field images were stitched together using photomerge in Photoshop
(Adobe). Bright-field time-lapse images were processed as movies in ImageJ.
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